drugset / Trial / NCT02610400

Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia

NCT02610400 ↗

RandomizedFactorialOpen-labelTreatment

Summary

This is a cluster randomised controlled trial with factorial study design comparing the impact of reactive community-based malaria interventions: 1) presumptive treatment (or rfMDA, reactive focal mass drug administration) versus reactive case detection (RACD), and 2) reactive IRS (indoor residual spraying) versus control on the incidence of malaria in Namibia.

Timeline

Start
2016-02
Primary completion
2017-12
Completion
2017-12

Outcome

Met primary endpoint

paper incidence of malaria was lower in clusters receiving rfMDA than in those receiving RACD (adjusted incidence rate ratio 0·52 [95% CI 0·16-0·88], p=0·009) PMID 32334702 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Artemether Small molecule 20 mg —
Subject Artemether Small molecule 40 mg —
Subject Artemether Small molecule 60 mg —
Subject Artemether Small molecule 80 mg —
Subject lumefantrine Small molecule 120 mg —
Subject lumefantrine Small molecule 240 mg —
Subject lumefantrine Small molecule 360 mg —
Subject lumefantrine Small molecule 480 mg —
Subject pirimiphos-methyl Small molecule — Other

Indications